Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid a analog SDZ MRL 953 in cancer patients

Blood

Volumn 90, Issue 4, 1997, Pages 1673-1683

  Kiani, Alexander ^b   Tschiersch, Astrid ^b   Gaboriau, Elke ^b   Otto, Florian ^b   Seiz, Alexander ^b   Knopf, Hans Peter ^b   Stütz, Peter ^b   Färber, Lothar ^b   Haus, Ulrike ^b   Galanos, Chris ^b   Mertelsmann, Roland ^b   Engelhardt, Rupert ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID A DERIVATIVE; SALMONELLA ENDOTOXIN; SDZ MRL 953; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEVER; GRAM NEGATIVE SEPSIS; HUMAN; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LIVER TOXICITY; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK;

EID: 0030808954     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.4.1673.1673_1673_1683     Document Type: Article

References (63)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA. Schein RMH, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644, 1992
2. Danner RL, Ellin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 99:169, 1991
3. Centers For Disease Control: National Nosocomial Infections Study Report. Annual Summary 1976. Washington, DC. US Department of Health, Education, and Welfare, 1978
4. Morrison DC, Ryan JL: Endotoxins and disease mechanisms. Annu Rev Med 38:417, 1987
5. Schumann RR, Rietschel ET: Endotoxin - Structure, recognition, cellular response and septic shock. Antiinfect Drugs Chemother 13:115, 1995
6. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481, 1988
7. Engelhardt R, Mackensen A, Galanos C, Anderesen R: Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Modif 9:480, 1990
8. Engelhardt R, Mackensen A, Galanos C: Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 51:2524, 1991
9. van Deventer SJH, Bul̈ller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76:2520, 1990
10. Tracey KJ, Beutler B. Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ III, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 234:470, 1986
11. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. J Clin Invest 81:1162, 1988
12. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869, 1985
13. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662, 1987
14. Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550, 1990
15. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 11:443, 1990
16. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 163:1177, 1991
17. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ: Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84:9233, 1987
18. Hack CE, De Groot ER, Felt-Bersma RJF, Nuijens JH, Strack Van Schijndel RJM, Eerenberg-Belmer AJM, Thijs LG. Aarden LA: Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704, 1989
19. Friedland JS, Suputtamongkol Y, Remick DG, Chaowagul W, Stricter RM, Kunkel SR, White NJ, Griffin GE: Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leucocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immun 60:2402, 1992
20. Gómez-Jímenez J, Martín MC, Sauri R, Segura RM, Esteban F, Ruiz JC, Nuvials X, Bóveda JL, Peracaula R, Salgado A: Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 171:472, 1995
21. Natanson C. Hoffmann WD, Suffredini AF, Eichacker PQ, Danner RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771, 1994
22. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA, The IL-1 RA Sepsis Syndrome Study Group: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22:12, 1994
23. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff GC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR, The HA-IA Sepsis Study Group: Treatment of gram-negative bacteremia and septic shock with HA-IA human monoclonol antibody against endotoxin. N Engl J Med 324:429, 1991
24. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548, 1993
25. Fisher CJ, Dhainaut J-FA, Opal SM. Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC, The Phase III rhIL-1ra Sepsis Syndrome Study Group: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 271:1836, 1994
26. Fisher CJ, Agosti JM. Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E, The Soluble TNF Receptor Study Group: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 334:1697, 1996
27. Luce JM: Introduction of new technology into critical care practice: A history of HA-IA human monoclonal antibody against endotoxin. Crit Care Med 21:1233, 1993
28. Mackensen A, Galanos C, Wehr U, Engelhardt R: Endotoxin tolerance: Regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytokine Netw 3:571, 1992
29. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R, Engelhardt R: Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer 32A:1712, 1996
30. Freudenberg MA, Galanos C: Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect Immun 56:1352, 1988
31. Ribi E: Beneficial modifications of the endotoxin molecule. J Biol Response Modif 3:1, 1984
32. Perera PY, Manthey CL, Stütz PL, Hildebrandt J, Vogel SN: Induction of early gene expression in murine macrophages by synthetic lipid A analogs with differing endotoxic potentials. Infect Immun 61:2015, 1993
33. Lam C, Schütze E, Hildebrandt J, Aschauer H, Liehl E, Macher I, Stütz P: SDZ MRL 953, a novel immunostimulatory mono-saccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob Agents Chemother 35:500, 1991
34. Lam C, Schütze E, Liehl E, Stütz P: Effect of SDZ MRL 953 on the survival of mice with advanced sepsis that cannot be cured by antibiotics alone. Antimicrob Agents Chemother 35:506, 1991
35. Westphal O, Lüderitz O, Bister F: Über die Extraktion von Bakterien mit Phenol-Wasser. Z Naturforsch 7:148, 1952
36. Galanos C, Lüderitz O, Westphal O: Preparation and properties of standardized lipopolysaccharide from Salmonella abortus equi (Novo Pyrexal). Zentralbl Mikrobiol 243:226, 1979
37. Galanos C, Lüderitz O: Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms. Eur J Biochem 54:603, 1975
38. Karnofsky DA: Meaningful clinical classification of therapeutic response to anticancer drugs. Clin Pharmacol Ther 2:709, 1961
39. Liehl E, Lam C, Mayer P, Schütze E, Bahr G, Großmüller F, Stütz P, Hildebrandt J: SDZ MRL 953, a new cytokine inducing agent and stimulant for nonspecific immunity, in Levin J, Alving CR, Munford RS, Stütz PL (eds): Bacterial Endotoxins: Recognition and Effector Mechanisms. Amsterdam, The Netherlands, Elsevier Science Publishers B.V., 1993, p 399
40. Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T: Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-Iβ: A study on IL-6 deficient mice. J Exp Med 183:311, 1996
41. Mackensen A, Galanos C, Engelhardt R: Modulating activity of interferon-γ on endotoxin-induced cytokine production in cancer patients. Blood 78:3254, 1991
42. Stern A, Engelhardt R. Foster C, Golenbock D, Hildebrandt J, Landmann R, Mayer P, Stütz P: SDZ MRL 953, a lipid A analog as selective cytokine inducer. Prog Clin Biol Res 392:549, 1994
43. Wright SD. Ramos RA. Tobias PS, Ulevitch RJ, Mathison RJ: CDI4, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431, 1990
44. Ingalls RR. Golenbock DT: CD 11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med 181:1473, 1995
45. Schletter J, Brade H, Brade L, Krüger C, Loppnow H, Kusumoto S, Rietschel ET, Flad H-D, Ulmer AJ: Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein. Infect Immun 63:2576, 1995
46. Astiz ME, Rackow EC, Still JG, Howell ST, Cato A, Von Eschen KB, Ulrich JT, Rudbach JA, McMahon G, Vargas R, Stern W: Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial. Crit Care Med 23:9, 1995
47. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JWM, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Dinarello CA: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79, 1990
48. Knopf H-P, Otto F, Engelhardt R, Freudenberg MA, Galanos C, Hermann F, Schumann RR: Discordant adaptation of human peritoneal macrophages to stimulation by lipopolysaccharide and the synthetic lipid A analogue SDZ MRL 953. J Immunol 153:287, 1994
49. Hartung T, Döcke W-D, Gantner F, Krieger G, Sauer A, Stevens P, Volk H-D, Wendel A: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482, 1995
50. Pollmächer T, Korth C, Mullington J, Schreiber W. Sauer J, Vedder H, Galanos C, Holsboer F: Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 87:900, 1996
51. Fahrni H, Chaby R: Selective refractoriness of macrophages to endotoxin-induced production of tumor necrosis factor, elicited by an autocrine mechanism. J Leukoc Biol 53:45, 1993
52. Laegreid A, Thommesen L, Gullstein Jahr T, Sundan A, Espevik T: Tumor necrosis factor induces lipopolysaccharide tolerance in a human adenocarcinoma cell line mainly through the TNF p55 receptor. J Biol Chem 270:25418, 1995
53. Randow F, Syrbe U, Meisel C, Krausen D, Zuckermann H, Platzer C, Volk H-D: Mechanism of endotoxin desensitization: Involvement of interleukin-10 and transforming growth factor β. J Exp Med 181:1887, 1995
54. Cavaillon J-M, Pitton C, Fitting C: Endotoxin tolerance is not a LPS-specific phenomenon: Partial mimicry with IL-I, IL-10 and TGFβ. J Endotoxin Res 1:21, 1994
55. Görgen I, Hartung T, Leist M, Niehörster M, Tiegs G, Uhlig S, Weitzel F, Wendel A: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-a. J Immunol 149:918, 1992
56. Fiorentino DF, Zlotnick T, Mosmann T, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815, 1991
57. Mathison J, Wolfson E, Steinemann S, Tobias P, Ulevitch RJ: Lipopolysaccharide (LPS) recognition in macrophages. J Clin Invest 92:2053, 1993
58. Ziegler-Heitbrock HWL, Frankenberger M, Wedel A: Tolerance to lipopolysaccharide in human blood monocytes. Immunobiology 193:217, 1995
59. Hill CS, Treisman R: Transcriptional regulation by extracellular signals: Mechanisms and specifity. Cell 80:199, 1995
60. Alexander HR, Sheppard BC, Jensen JC, Langstein HN, Buresh CM, Venzon D, Walker EC, Fraker DL, Stovroff MC, Norton JA: Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest 88:34, 1991
61. Van der Meer JW, Barza M, Wolff SM, Dinarello CA: A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 85:1620, 1988
62. Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Krönke M, Mak TW: Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457, 1993
63. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom RW: Tumor necrosis factor-α is required for the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561, 1995